US EditionJapan Offers Competitive Edge With Clinical Trial Landscape And SMO Approach - Data Intelligence
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Japan Offers Competitive Edge With Clinical Trial Landscape And SMO Approach - Data Intelligence
An expert from a CRO-SMO discusses Japan’s advantages as a clinical trial site. Credit: Athanasios Psimadis / Arena International Events. “Japan has the second biggest market for branded drugs and is the third largest market for pharmaceuticals overall,” says Kento Nakamura, strategy and corporate development at the CMIC Group, thereby presenting a fertile ground for clinical trial operations. Nakamura, who works for the contract research organi…
Japan offers competitive edge with clinical trial landscape and SMO approach
An expert from a CRO-SMO outlines Japan's advantages as a potential clinical trial site, in terms of services and regulatory landscape.The post Japan offers competitive edge with clinical trial landscape and SMO approach appeared first on Clinical Trials Arena.
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
